Your session is about to expire
← Back to Search
Other
DAIN Diet for Crohn's Disease (DAIN Trial)
N/A
Recruiting
Led By Ana L Maldonado-Contreras, PhD
Research Sponsored by University of Massachusetts, Worcester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0, 6, 10, 14
Awards & highlights
No Placebo-Only Group
Summary
This trial studies a diet intervention to treat Crohn's disease in Puerto Ricans, based on the IBD-AID™ diet, with traditional foods.
Who is the study for?
This trial is for adults aged 21-65 with mild to moderate Crohn's disease who are willing to significantly change their diet. Participants must have stable medication doses and be able to follow study procedures. Those on high-dose steroids, recent C. difficile colitis, ostomies, or using certain diets or probiotics within the last month cannot join.
What is being tested?
The DAIN dietary intervention is being tested for its effectiveness in treating Crohn's disease symptoms. It adapts the IBD-AID™ by incorporating Puerto Rican food preferences while keeping key anti-inflammatory components intact.
What are the potential side effects?
Since this trial involves a dietary intervention (DAIN), side effects may include changes in digestion such as discomfort or altered bowel habits as participants adjust to new foods.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 0, 6, 10, 14
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0, 6, 10, 14
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Improvement of health-related quality of life
Secondary study objectives
Change of Inflammation
Clinical response and remission
Dietary compliance
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm1: Crohn's disease patients + DAINExperimental Treatment1 Intervention
Participants will have 10 weeks of DAIN intervention (From week 1 to week 10)
Group II: Arm 2: Crohn's disease patients no interventionActive Control1 Intervention
Participants will continue consuming their usual diet, with no intervention
Find a Location
Who is running the clinical trial?
University of Puerto RicoOTHER
67 Previous Clinical Trials
22,135 Total Patients Enrolled
University of Massachusetts, WorcesterLead Sponsor
362 Previous Clinical Trials
992,570 Total Patients Enrolled
The Leona M. and Harry B. Helmsley Charitable TrustOTHER
66 Previous Clinical Trials
99,545 Total Patients Enrolled
Ana L Maldonado-Contreras, PhDPrincipal InvestigatorUniversity of Massachusetts Chan Medical School
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I take more than 20mg of prednisone or its equivalent daily.My medication doses have been stable for the required time.I am willing and able to make major changes to my diet.I am between 21 and 65 years old.I recently had a C. difficile infection in my colon.I have had a blockage in my body or symptoms of one in the last 6 months.I have been diagnosed with Crohn's disease and my symptoms are mild to moderate.I have not taken any probiotics in the last 4 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: Arm1: Crohn's disease patients + DAIN
- Group 2: Arm 2: Crohn's disease patients no intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.